Patents by Inventor Walter A. Blattler

Walter A. Blattler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020013485
    Abstract: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.
    Type: Application
    Filed: August 21, 2001
    Publication date: January 31, 2002
    Inventors: Ravi V.J. Chari, Walter A. Blattler
  • Patent number: 6340701
    Abstract: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. Novel sulfur-containing taxanes.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: January 22, 2002
    Assignee: Immunogen INC
    Inventors: Ravi V. J. Chari, Walter A. Bl├Ąttler
  • Publication number: 20010036923
    Abstract: A cytotoxic agent comprising one or more modified doxorubicins/daunorubicin linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more modified doxorubicins/daunorubicins covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier. A method for killing selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more modified doxorubicins/daunorubicins linked to a cell binding agent. Novel sulfur-containing modified doxorubicins/daunorubicins.
    Type: Application
    Filed: December 21, 2000
    Publication date: November 1, 2001
    Inventors: Ravi V.J. Chari, Walter A. Blattler
  • Patent number: 5846545
    Abstract: Gytotoxic agents containing a cell binding agent chemically linked to one or more analogue or derivative of CC-1065 are described. The therapeutic use of the cytotoxic agents is also described. These cytotoxic agents have therapeutic use because they deliver the cytotoxic drugs to a specific cell population in a targeted fashion.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 8, 1998
    Assignee: Immunogen, Inc.
    Inventors: Ravi V. J. Chari, Viktor S. Goldmakher, Walter A. Blattler
  • Patent number: 5585499
    Abstract: Novel cytotoxic agents comprising a cell binding agent chemically linked to one or more analogue or derivative of CC-1065 are described. The therapeutic use of the cytotoxic agents is also described. These cytotoxic agents have therapeutic use because they deliver the cytotoxic drugs to a specific cell population in a targeted fashion.
    Type: Grant
    Filed: July 6, 1995
    Date of Patent: December 17, 1996
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Viktor S. Goldmakher, Walter A. Blattler
  • Patent number: 5475092
    Abstract: Novel cytotoxic agents comprising a cell binding agent chemically linked to one or more analogue or derivative of CC-1065 are described. The therapeutic use of the cytotoxic agents is also described. These cytotoxic agents have therapeutic use because they deliver the cytotoxic drugs to a specific cell population in a targeted fashion.
    Type: Grant
    Filed: March 21, 1994
    Date of Patent: December 12, 1995
    Assignee: Immunogen Inc.
    Inventors: Ravi V. J. Chari, Viktor S. Goldmakher, Walter A. Blattler
  • Patent number: 5416064
    Abstract: A cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. A therapeutic agent for killing selected cell populations comprising: (a) a cytotoxic amount of one or more maytansinoids linked to a cell binding agent, and (b) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting a cell population or tissue suspected of containing cells from said selected cell population with a cytotoxic amount of a cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. An N-methyl-alanine-containing ester of maytansinol or an analogue of maytansinol, said N-methyl-alanine-containing ester comprising a linking group capable of linking an N-methyl-alanine-containing maytansinoid ester to a chemical moiety. N-methyl-cysteine-containing ester of maytansinol or an analogue of maytansinol.
    Type: Grant
    Filed: December 7, 1992
    Date of Patent: May 16, 1995
    Assignee: ImmunoGen, Inc.
    Inventors: Ravi J. Chari, Victor S. Goldmacher, John M. Lambert, Walter A. Blattler
  • Patent number: 5395924
    Abstract: An activated affinity ligand is described comprising: a ligand having (a) a region with affinity for binding sites of a lectin; and (b) a reactive group capable of covalently linking the ligand to the lectin to thereby block one or more of the binding sites of the lectin. A blocked lectin is described comprising one or more affinity ligands covalently linked by means of a reactive group present on each of the ligands to a lectin such that one or more binding sites of the lectin is blocked. A cell-binding agent-blocked lectin conjugate is described comprising the above-described blocked lectin and a cell-binding agent covalently linked to: (a) one of the covalently linked affinity ligands; or (b) the lectin. A method of preparing the cell-binding agent-blocked lectin conjugate is described. An affinity support capable of binding to a lectin to form a blocked lectin is described comprising an activated affinity ligand covalently linked to a solid support.
    Type: Grant
    Filed: February 19, 1993
    Date of Patent: March 7, 1995
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Walter A. Blattler, John M. Lambert, Victor S. Goldmacher, Ravi V. J. Chari, Charles F. Scott, Jr., Linda J. Kostuba, Simon E. Moroney, Albert R. Collison
  • Patent number: 5239062
    Abstract: An activated affinity ligand is described comprising: a ligand having (a) a region with affinity for binding sites of a lectin; and (b) a reactive group capable of covalently linking the ligand to the lectin to thereby block one or more of the binding sites of the lectin. A blocked lectin is described comprising one or more affinity ligands covalently linked by means of a reactive group present on each of the ligands to a lectin such that one or more binding sites of the lectin is blocked. A cell-binding agent-blocked lectin conjugate is described comprising the above-described blocked lectin and a cell-binding agent covalently linked to: (a) one of the covalently linked affinity ligands; or (b) the lectin. A method of preparing a blocked lectin is described. A method of preparing the cell-binding agent-blocked lectin conjugate is described. An affinity support capable of binding to a lectin to form a blocked lectin is described comprising an activated affinity ligand covalently linked to a solid support.
    Type: Grant
    Filed: July 31, 1990
    Date of Patent: August 24, 1993
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Walter A. Blattler, John M. Lambert, Victor S. Goldmacher, Ravi V. J. Chari, Charles F. Scott, Jr., Linda J. Kostuba, Simon E. Moroney, Albert R. Collinson
  • Patent number: 5208020
    Abstract: A cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. A therapeutic agent for killing selected cell populations comprising: (a) a cytotoxic amount of one or more maytansinoids linked to a cell binding agent, and (b) a pharmaceutically acceptable carrier diluent or excipient. A method for killing selected cell populations comprising contacting a cell population or tissue suspected of containing cells from said selected cell population with a cytotoxic amount of a cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. An N-methyl-alanine-containing ester of maytansinol or an analogue of maytansinol, said N-methyl-alanine-containing ester comprising a linking group capable of linking an N-methyl-alanine-containing maytansinoid ester to a chemical moiety. N-methyl-cysteine-containing ester of maytansinol or an analogue of maytansinol.
    Type: Grant
    Filed: July 13, 1992
    Date of Patent: May 4, 1993
    Assignee: ImmunoGen Inc.
    Inventors: Ravi J. Chari, Victor S. Goldmacher, John M. Lambert, Walter A. Blattler
  • Patent number: 4888415
    Abstract: Immunotoxins having improved toxic activity have the composition ##STR1## wherein Toxin-NH is a ribosome-inactivating protein containing no accessible sulfhydryl groups, n is an integer from 1 to 5, m is an integer from 1 to 5, and NH-Antibody is a monoclonal antibody specific to eucaryotic cells or antigens associated therewith. The immunotoxins are made by reacting the Toxin-NH with an iminothiolester salt to form a first conjugate, reacting the NH-Antibody with N-succinimidyl-3-(2-pyridyldithio) propionate to form a second conjugate, and reacting the two conjugates to form the immunotoxin.
    Type: Grant
    Filed: March 7, 1988
    Date of Patent: December 19, 1989
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: John M. Lambert, Walter A. Blattler, Peter D. Senter
  • Patent number: 4764368
    Abstract: Heterobifunctional reagents that are cleavable under mildly acidic conditions are disclosed. The reagents include an acid cleavable cyclohexene-1,2,-dicarboxylic acid monoamide group. Also disclosed are methods of making the cross-linkers, as well as methods of using the cross-linkers, e.g., to deliver a biologically active substance across the membranes of selected cells in a heterogeneous cell population; once inside the cell the active substance is released, intact, by the transient, mild acidity of certain cell structures. Finally, a method of characterizing complex multi-chain protein structures is disclosed.
    Type: Grant
    Filed: September 17, 1986
    Date of Patent: August 16, 1988
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Walter A. Blattler, John M. Lambert
  • Patent number: 4625014
    Abstract: A photo-cleavable compound for delivery and release of a biologically active substance to selected target cells; the compound includes a binding partner for a specific cell-surface receptor of those target cells, the biologically active substance to be delivered, and a photo-cleavable bridge between the binding partner and the biologically active substance. When the compound is exposed to a heterogeneous population of target and non-target cells, it binds selectively to the receptors on the surface of the target cells. Exposing the compound to light of selected wave length cleaves it, yielding the active substance.
    Type: Grant
    Filed: July 10, 1984
    Date of Patent: November 25, 1986
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Peter D. Senter, John M. Lambert, Walter A. Blattler
  • Patent number: 4618492
    Abstract: Amino-sulfhydryl cross-linking reagents that are cleavable under mildly acidic conditions are disclosed. Also disclosed are methods of making the cross-linkers, as well as methods of using the cross-linkers, e.g., to deliver a biologically active substance across the membranes of selected cells in a heterogeneous cell population; once inside the cell the active substance is released, intact, by the transient, mild acidity of certain cell structure. Finally, a method of characterizing complex multi-chain protein structures is disclosed.
    Type: Grant
    Filed: May 13, 1985
    Date of Patent: October 21, 1986
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Walter A. Blattler, John M. Lambert, Peter D. Senter
  • Patent number: 4569789
    Abstract: Amino-sulfhydryl cross-linking reagents that are cleavable under mildly acidic conditions are disclosed. Also disclosed are methods of making the cross-linkers, as well as methods of using the cross-linkers, e.g., to deliver a biologically active substance across the membranes of selected cells in a heterogeneous cell population; once inside the cell the active substance is released, intact, by the transient, mild acidity of certain cell structures. Finally, a method of characterizing complex multi-chain protein structures is disclosed.
    Type: Grant
    Filed: April 26, 1985
    Date of Patent: February 11, 1986
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Walter A. Blattler, John M. Lambert, Peter D. Senter
  • Patent number: 4542225
    Abstract: Amino-sulfhydryl cross-linking reagents that are cleavable under mildly acidic conditions are disclosed. Also disclosed are methods of making the cross-linkers, as well as methods of using the cross-linkers, e.g., to deliver a biologically active substance across the membranes of selected cells in a heterogeneous cell population; once inside the cell the active substance is released, intact, by the transient, mild acidity of certain cell structures. Finally, a method of characterizing complex multi-chain protein structures is disclosed.
    Type: Grant
    Filed: August 29, 1984
    Date of Patent: September 17, 1985
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Walter A. Blattler, John M. Lambert, Peter D. Senter